FDA Brief

Warning letters Food

FDA warning letter to

Lyons Magnus, LLC

High riskIssued Jan 30, 2023Posted Feb 14, 2023Division of Human and Animal Food Operations West I

FDA warned Lyons Magnus about microbial contamination in aseptic low-acid beverages and delayed reporting of contaminated lots.

What happened

FDA inspected Lyons Magnus’s Beloit, Wisconsin aseptic processing facility from August 3 to September 14, 2022, after the firm’s July 2022 recall of all low-acid canned food products made there for potential Cronobacter sakazakii and Clostridium botulinum contamination; FDA had also inspected May 23 to June 10, 2022. The inspections found serious violations of the emergency permit control and low-acid canned food regulations, including shipped batches with gram-positive rods, gram-negative rods, or cocci, failure to promptly report contaminated lots, and cleaning/sterilization failures.

What FDA found

  1. The firm did not promptly report to FDA that lots with microbial contamination had entered distribution.

    21 CFR 108.35(e)
  2. The firm did not bring the product sterilizer and all product-contact surfaces to commercial sterility (free of viable microorganisms) before aseptic processing.

    21 CFR 113.40(g)(1)(ii)(A)
  3. The firm shipped products containing viable microorganisms that did not meet the definition of commercial sterility.

    21 CFR 113.3(e)(1)(i)(a); section 301(a) of the Act
  4. Operators recorded pass/fail instead of actual critical-factor values, and the electronic records could not be reviewed as a complete process.

    21 CFR 113.100(a)(4); 21 CFR 108.35(h)
  5. The firm did not document enough information to support clearing process deviations, including product leaks.

    21 CFR 113.89
  6. After loss of sterility, the firm did not return the system to commercial sterility before resuming packaging operations.

    21 CFR 113.40(g)(2)(ii)(B)

What FDA wants

FDA tells Lyons Magnus to correct the violations, investigate and determine their causes, and prevent recurrence; the provided letter does not state a response deadline.

Who should pay attention

  • brands that contract-manufacture nutritional drinks or plant-based beverages
  • food companies using aseptic low-acid processing
  • retailers and consumers of the recalled beverage products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk